Assembly Biosciences is a biotech company in the US that focuses on developing therapeutic candidates to treat chronic hepatitis B virus (HBV) infection. Its lead product candidate, Vebicorvir, has completed Phase 2 clinical trials, while it continues to develop ABI-H3733 (completed Phase 1a clinical study) and ABI-4334 (pre-clinical trials) to treat HBV. The company also has collaboration and license agreements with other biopharma and research organizations.